Summit Therapeutics
-
马斯克重磅宣布Neuralink最新计划；中国抗体药物接连出海；Summit PD-1/VEGF双抗三期临床OS积极，但股价大跌30%；Biogen进军CNS研发；罗氏与Orionis Biosciences达成第二笔交易
每日发布，持续更新。欢迎广大朋友们关注，一起学习进步！
-
Is it too early for Akeso and Summit to celebrate? Merck executive comments on the explosive news that Keytruda has been successfully challenged
Just our two cents. All comments, including criticisms, are warmly welcome. Thank you all very much!
-
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Tri…
